In this study, we investigated SNPs in the genes CES1/2, CES1P1, CDA, and TYMP, which encode enzymes involved in the bioactivation of capecitabine and could potentially influence susceptibility to treatment-related toxicity in patients with CRC. Here, CDA is linked to colorectal carcinoma.